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KEY POINTS 
1. Allogeneic HSCT with reduced intensity conditioning is safe and effective in younger adults with 
severe PID. 
2. Referral triggers should include severe infections, autoimmunity, malignancy and disease 
progression despite conservative management. 
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ABSTRACT   
 
Introduction The primary immunodeficiencies (PID), rare inherited diseases characterised by severe 
dysfunction of immunity have been successfully treated by allogeneic hematopoietic stem cell 
transplantation (Allo-HSCT) in childhood. Controversy exists regarding optimal timing and use of Allo-HSCT in 
adults, due to lack of experience and previous poor outcomes.  
Materials and methods 29 consecutive adult patients, with a mean age at transplant of 24 years (range 17-
50) underwent Allo-HSCT. Reduced intensity conditioning included Flu/Mel/Alemtuzumab (n=20), 
Flu/Bu/Alemtuzumab (n=8) and Flu/Bu/ATG (n=1). Stem cell donors were matched or mismatched unrelated 
(MUD/MMUD) (n=18) and matched related donors (MRD) (n=11). Overall survival, event free survival, 
transplant related mortality, acute and chronic GVHD incidence and severity, time to engraftment, lineage 
specific chimerism, immune reconstitution and discontinuation of immunoglobulin replacement therapy 
were recorded.  
Results Overall survival (OS) at 3 years for the whole cohort was 85.2%. The rarer, non-CGD PID patients 
achieved an OS at 3 years of 88.9% (n=18), compared to 81.8% for CGD patients (n=11). Transplant related 
mortality (TRM) was low with only four deaths observed at a median follow-up of 3.5 years. There were no 
cases of early or late rejection. In all surviving patients either stable mixed chimerism or full donor 
chimerism were observed. At last follow-up 87% of the surviving patients had no evidence of persistent or 
recurrent infections. 
Conclusion Allo-HSCT is safe and effective in young adult patients with severe PID and should be considered 
the treatment of choice where an appropriate donor is available.  
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INTRODUCTION 
 
The primary immunodeficiencies (PID) are a rare group of inherited diseases characterised by severe 
dysfunction of adaptive and/or innate immunity, typically arising from genetic mutations in hematopoietic 
stem cells. Nearly 300 distinct immunodeficiencies have now been described, with 20 accounting for over 
90% of cases. Excluding common variable immunodeficiency (CVID), three of the most common are severe 
combined immunodeficiency (SCID), Wiskott-Aldrich syndrome (WAS) and chronic granulomatous disease 
(CGD). Children with severe PIDs have been successfully treated by allogeneic hematopoietic stem cell 
transplantation (Allo-HSCT), which has been the major therapeutic option for inherited cellular 
immunodeficiency disorders since 1968
1-6
. However, almost all series published on outcomes for Allo-HSCT 
have focussed on pediatric patients. The median age at transplant of patients described in the largest 
published series are < 1 year for SCID
7
, 2.8 years for WAS
8
 and 12.7 years for CGD, utilising reduced intensity 
conditioning (RIC)
9, 10
. 
 
Significant advances in hematopoietic transplantation over the past 20 years including refinement of HLA-
tissue typing, adoption of RIC regimens, increased availability of alternative stem cell sources, improved 
methods of graft-versus-host disease (GvHD) prophylaxis and improved supportive care have translated into 
better outcomes today compared to the early experience
5, 11
.  
 
Early Allo-HSCT is important in infants or children presenting with serious or life-threatening infections as 
without definitive treatment, patients with severe PID, such as SCID, rarely survive beyond 1 year of age. In 
addition, younger patients have less end-organ damage from repeated or severe infections
11, 12
. Indeed, 
overall survival has been shown to fall from 95% in SCID patients transplanted at ages less than 3.5 months 
to 76% in older children
7,
 
13
. 
 
Whilst early Allo-HSCT is preferred for PID, this is often not possible. An initial milder clinical phenotype, 
delayed diagnosis, late presentation, lack of a genetic diagnosis or an inability to identify a suitable stem cell 
donor may result in patients surviving to adolescence and early adulthood without having undergone Allo-
HSCT. Furthermore, in non-SCID forms of PID, the clinical phenotype can be very heterogeneous and 
‘atypical’, largely due to the high number of genetic and functional defects affecting T, B and NK cells, 
neutrophils and/or antigen presentation. For these patients, diagnosis can be delayed or difficult and the 
natural history of exceptionally rare underlying diseases is often unclear. In several PIDs, controversy 
surrounding optimum timing of Allo-HSCT remains, due to rarity of disease, lack of experience, emerging 
gene therapies
14-17 
and infrequent published outcome data due to the very low numbers in any one centre.
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One such disorder where optimum timing remains unclear is CGD, which is characterised by impairment of 
the phagocyte NADPH-oxidase complex. Patients with absent NADPH activity are one group thought to 
benefit from early transplant
18
 and criteria have been devised for Allo-HSCT in children. These are: life-
threatening infection, non-compliance with antimicrobial prophylaxis or steroid-dependent auto-
inflammatory disease
19
. In adolescents and adults, criteria are more difficult to apply due to higher rates of 
organ dysfunction and reported increased mortality from Allo-HSCT
20
. The largest published case series 
reported a cohort of 70 CGD patients with excellent overall survival of 91.4% at median follow up (34 
months), but this cohort had a median age of 8.9 years (interquartile range 3.8 to 19.3 years)
10. 
Similarly,
 
the 
second largest series of 56 CGD patients also had an excellent overall survival of 93% at median follow up (21 
months), but again the median age was young at 12.5 years
9
 with only 14 patients aged ≥ 17 years of age.  
 
There is even less experience of Allo-HSCT in rarer PIDs and the literature is confined to pediatric series or 
adult case reports. In the lethal genetic PID caused by GATA2 mutations, HSCT has resulted in reversal of the 
hematologic, immunologic and clinical phenotype in small series including adults
21, 22
. In addition, in XIAP 
deficiency, poor outcomes post Allo-HSCT have been reported, with high rates of transplant related 
mortality (TRM)
23
, although a recent paper has described excellent outcome for 10 Japanese patients (all < 
17 years) undergoing RIC conditioned HSCT
24
. 
 
Given the reduced toxicity of RIC regimens, these appear to be better tolerated in patients with PID who 
often have significant organ dysfunction and associated elevated haematopoietic cell transplant-comorbidity 
index (HCT-CI) scores
25
 pre-transplant. Elsewhere others have used low toxicity myeloablative conditioning 
regimens incorporating targeted treosulfan with excellent results in children
26, 27
. 
 
We report here the outcome of 29 consecutive adult patients (≥ 17 years) who underwent Allo-HSCT for a 
variety of PIDs in the Allo-HSCT programmes of University College London Hospitals NHS Foundation Trust 
and the Royal Free London Hospital NHS Foundation Trust, UCL Centre for Immunodeficiency, July 2004 - 
November 2016. Prior to transplant all patients had developed complications that necessitated definitive 
treatment with curative intent. During the study period, 5 additional adult patients were referred for 
consideration of Allo-HSCT who did not proceed to transplant. Referral was triggered by life-threatening 
infection, malignancy, autoimmune or inflammatory phenomena, new genetic diagnosis or new donor 
availability. 
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METHODS 
 
Study Design and Participants  
All patients provided written consent as per institutional practice for Allo-HSCT. The mean age at transplant 
was 24 years (range 17-50 years). Of these, 11 patients had CGD and 18 had various other PID. Detailed 
patient demographics and transplant characteristics are shown in Table 1. Primary immunodeficiencies were 
diagnosed using international criteria. Patients with severe dysfunction of adaptive and/or innate immunity 
can present with recurrent infections, autoimmunity and/or malignancy. 19 patients had a genetic diagnosis 
and 10 had a combination of clinical phenotype with a corresponding functional defect. Secondary causes of 
immunodeficiency were excluded. Data on donor status, conditioning regimen, clinical condition during and 
after transplant and at last follow up was collected retrospectively from the medical notes and our Allo-HSCT 
database. The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a comorbidity tool, which 
captures the prevalence, magnitude and severity of various organ impairments before Allo-HSCT in order to 
predict risk of transplant related mortality (TRM). HCT-CI scores pre-transplant were calculated for all 
patients
22
.
 
All patients had a score of ≥1 whilst 12 (41%) had a score of ≥3. HCT-CI scores were higher in the 
PID cohort (50% scored ≥3) compared to the CGD cohort (27% scored ≥3), which was not statistically 
significant (p=0.206), but may suggest an increased risk of TRM. 
 
Stem Cell Source  
11 patients had matched related donors (10 siblings, 1 10/10 matched paternal donor) and 18 had matched 
unrelated donors, including 5 with 1 antigen mismatched unrelated donors (4 A antigen mismatch, 1 C 
antigen mismatch). Patients and donors were matched for human leucocyte antigen (HLA) A, B, C, DRB1 and 
DQB1 by intermediate or high-resolution DNA-typing as appropriate. 
Mobilised peripheral blood stem cells (PBSC) were the stem cell source in 79% of the patients (n=23, 
including all non-CGD patients) whilst bone marrow was used in the other 21% (n=7, all CGD patients).  
 
Allo-HSCT Conditioning Regimen  
All patients were transplanted using previously described T cell-depleted (in vivo alemtuzumab or 
antithymocyte globulin, ATG) reduced intensity conditioning regimens
9,28,29
. All non-CGD PID patients 
received fludarabine (30mg/m
2 
daily for 5 days), melphalan 140mg/m
2
 and alemtuzumab (100mg for MUD 
recipients delivered as 20mg OD, days -7 to day -3 and 30mg single dose on day -1 for MRD recipients after 
May 2010). Two of the early MRD patients also received 100mg alemtuzumab delivered as 20mg OD, days -7 
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to day -3. Conditioning for CGD patients consisted of fludarabine (30mg/m
2
 daily for 5 days), busulfan 
(1.6mg/kg twice daily for 3 days) or melphalan (140mg/m
2
 total), together with alemtuzumab (0.2mg/kg 
daily for 3 days) for 10 patients or, in one patient, rabbit anti-thymocyte globulin (rATG) (2.5mg/kg daily for 
3 days). The mean busulfan cumulative AUC was 56.05 (umol/L)(min) (range 44.34-62.66, n=7).  Details are 
shown in Table 1.  
 
In addition to antibody-mediated in vivo T cell depletion, GVHD prophylaxis with cyclosporine was used in all 
patients. Acute and chronic GVHD were graded as previously reported
30,31
.  
 
Supportive Care  
Reverse isolation, antimicrobial and antifungal prophylaxis were used to reduce the risk of infectious 
complications. All patients received prophylaxis against Pneumocystis jiroveci and acyclovir prophylaxis 
against varicella zoster virus reactivation. Surveillance for cytomegalovirus (CMV), adenovirus (ADV) and 
Epstein Barr virus (EBV) infection was performed by weekly polymerase chain reaction or antigenemia 
testing, and pre-emptive treatment was administered according to institutional guidelines. 
In patients who were receiving immunoglobulin replacement therapy prior to transplant this was continued 
until normal trough levels were demonstrated post transplant and the risk of further infectious 
complications was minimal.  
 
Chimerism analysis   
Chimerism samples were processed at 3-monthly intervals until 1 year post transplant and then 6 monthly or 
when indicated clinically (cytopenias, persistent infections, ongoing mixed chimerism). In patients with a sex-
mismatched donor, chimerism was analysed by fluorescence in situ hybridization. In those with sex-matched 
donors, polymerase chain reaction of short tandem repeats was used. Lineage specific chimerism was 
performed on PBMC, T cell, B cell and granulocyte compartments. The laboratory reports results as follows; 
‘donor’ where donor DNA ≥ 97%, ‘mixed’ where donor DNA ≥ 50% and <97%, ‘very mixed’ where there is 
more recipient than donor DNA (donor DNA ≥ 1% <50%) and ‘recipient’ where no donor DNA can be 
detected. 
 
Study endpoints and statistical analysis  
Data were analysed in April 2017, in accordance with published guidelines
32, 33
. Primary outcome measures 
were overall survival (OS), event free survival (EFS), transplant related mortality (TRM), neutrophil 
engraftment and platelet engraftment. OS was defined as the time from transplant to death from any cause. 
EFS was defined as the time from transplant to graft failure, graft rejection or death from any cause. 
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Probabilities of OS and EFS were calculated using the Kaplan-Meier method with SPSS 22.0 statistical 
package (SPSS, Chicago, IL, USA). Comparison of survival curves was made using the log-rank method.  
Cumulative incidence estimates were used to calculate TRM and engraftment of neutrophils (≥0.5x10
9
/L) 
and platelets (≥50x10
9
/L) was calculated using.  
 
 
 
RESULTS 
 
Survival  
Overall survival of the whole cohort was 89.2% at 1 year and 85.2% at 3 years, with a mean follow up of 3.5 
years (range 4 months – 12 years). Overall survival at 1 year was 90.9% and 77.9% at 3 years for MRD 
transplants (n=11) and 94.4% at 1 year and 88.9% at 3 years for M/MUD transplants, p=0.51 (n=18). Overall 
survival was 90.9% at 1 year and 81.8% at 3 years for CGD patients (n=11) and 94.4% at 1 year and 88.9% at 
3 years for other PIDs, p=0.75  (n=18) (Figures 1A-1C).  
Event-free survival for the whole cohort was 89.7% at 1 and 3 years (n=29), with no significant difference 
observed for EFS between MRD transplants and M/MUD transplants; 90.9% vs 88.9% respectively (p=0.73). 
There was no significant difference in EFS in patients with CGD and other PID; 90.9% vs 88.9% at 1 and 3 
years (p=0.65) (Figures 1D-1F). One late death occurred in a patient over 9 years post transplant due to 
respiratory complications in the context of progression of pre-existing bronchiectasis. 
 
Engraftment  
There were no episodes of graft rejection or graft failure. For the whole cohort, neutrophil engraftment 
occurred after a median 12 days (mean 14, interquartile range 11-17) and median platelet engraftment was 
14 days (mean 17, interquartile range 11-20). Comparing MRD to MUD/MMUD, median time to neutrophil 
engraftment was 11 (IQR 11-12) versus 15 (IQR 12-21) days respectively (Figure 2A). Comparing the two 
diagnostic groups, time to neutrophil engraftment was longer in patients with CGD (n=11), median 16 days 
(IQR 12-22) versus 11 days (IQR 11-14) in patients with other PIDs (n=18) (Figure 2B). The observed longer 
time to engraftment in the CGD group reflects the fact that 7 of 11 CGD patients had BM as the stem cell 
source compared to the non-CGD PID patients who all received PBSC. 
Median time to platelet engraftment in MRD transplants was 12 days (IQR 11-21) and 18 days (IQR 12-21) in 
MUD/MMUD transplants (Figure 2C). Longer platelet engraftment was also seen in CGD patients, median 19 
days (IQR 14-20) compared to 16 days (IQR 11-21) in patients with other PIDs (Figure 2D). None of the 
observed differences were statistically significant. One patient had a CD34
+
 selected stem cell top-up due to 
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persistent cytopenias, with good effect. 
 
Transplant related mortality  
Conditioning was generally well tolerated with no cases of interstitial pneumonitis, veno-occlusive disease or 
severe mucositis (grade III-IV). Transplant related mortality was low with only four deaths observed at a 
median follow-up of 31 months for the whole cohort (n=29) (Figures 3A-3C). Two patients died during the 
neutropenic phase, prior to engraftment, of multi organ failure secondary to sepsis (one had no active 
infection immediately prior to transplant and the other had chronic cholangiopathy and was on 
antimicrobial prophylaxis), one at 7 months post-transplant of granulomatous meningoencephalitis and a 
further patient at 28 months post transplant secondary to sepsis in the context of chronic extensive GVHD.  
 
Graft versus host disease  
13 patients developed grades I-II acute GVHD (10 skin only, 1 skin and gut, 1 gut only and 1 liver only) and 
one patient developed grade III aGVHD of the liver.  Of these, 7 progressed to limited (single organ) chronic 
GVHD (4 skin only, 2 gut only and 1 pulmonary). A further patient developed steroid refractory extensive 
cGVHD. At last follow-up no patients had ongoing active cGVHD requiring systemic immune suppression. 
 
Infectious Complications 
A large proportion of patients had a high infectious burden pre-transplant as expected in patients with PID. 
Of the 29 patients, 24 (82%) had prior recurrent or severe infections, including recurrent bacterial infection 
(n=8), recurrent viral infection (n=7), both bacterial and systemic fungal infections (n=3), systemic fungal 
infection (n=2), both viral and bacterial infection (n=2), atypical mycobacterial infection (n=1) and combined 
viral and atypical mycobacterial infection (n=1). One patient had active pulmonary aspergilloma and three 
patients had ongoing HPV infection at the time of transplant (indicated in Table 1). Despite this, there was a 
distinct absence of major infection issues both intra and immediately post Allo-HSCT in our cohort. No 
patients suffered serious fungal infection post transplant, although azole prophylaxis was continued until off 
CSA in patients with pre-existing fungal infection  (Table 2). No patients required granulocyte infusions. 
CMV reactivation was only observed in 6 patients (35% of at risk patients, defined as +/+, -/+ or +/- 
recipient/donor pairs) and in all cases these responded to standard antiviral therapy. EBV reactivation with 
evidence of PTLD was observed in 4 patients all of whom responded completely to rituximab. An additional 
patient was treated with donor lymphocyte infusions (DLI) for presumed PTLD where no biopsy was 
available (n=1). No patient died of CMV, EBV or adenoviral infection. 
Five patients had persistent viral warts pre-transplant with complete resolution or ongoing resolution of 
warts observed at last follow-up in two patients. In three patients, no improvement in warts was observed, 
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despite full donor T cell chimerism in all, including the two patients transplanted for DCML deficiency, who 
had pre-existing extensive perineal HPV-related intraepithelial neoplasia (VIN/CIN or AIN). A further patient 
with extensive confluent warts pre-transplant (NK deficiency) had persistent warts despite full reconstitution 
of T, B and NK cells. 
At last follow-up the remaining 21 patients had no evidence of persistent or recurrent infections. 
 
Immune Reconstitution  
Lymphocyte subset analysis was performed on all the PID patients pre-transplant. Lymphocyte subset 
analysis was performed on all patients surviving beyond 3 months post-transplant (n=27) within the first 12 
months post-transplant. Of the non-CGD PID patients (n=18), 13 of the 16 surviving PID patients had 
lymphocyte subset results at 12 months (3 had not reached 12 months follow up at the time of data 
collection). 70% of those with subset analysis performed (n=13) had achieved a normal lymphocyte count 
(1.0-2.8 x 10
9
/L), 62% had normal absolute CD3+ cell counts (0.7-2.1 x 10
9
/L), 62% normal CD4+ cell counts 
(0.3-1.4 x10
9
/L) and 77% normal CD8+ cell counts (0.2-0.9 x10
9
/L).  
All CGD patients had normal neutrophil function tests post transplant (data not shown). 
Of the 9 surviving patients who had been receiving monthly immunoglobulin replacement therapy pre-
transplant, 89% were immunoglobulin-free at last follow up (Table 2). 
 
Chimerism 
Chimerism data was available for 23 of the 24 surviving patients at last follow up. At the time of analysis, 21 
patients had results available at 12 months post transplant and 85% had full donor chimerism in 
unfractionated PBMCs. In the T cell fraction 52% of patients tested had achieved full donor chimerism at 12 
months (Figure 4). 
Multilineage full donor chimerism was observed in 10 (48%) of the patients with the rest showing mixed 
chimerism in at least one of the cell lineages tested.  A trend to increasing chimerism stability with time was 
observed in our cohort. Chimerism was more robust in the B and myeloid cells compared to the T cell 
fraction. No correlation was found between mixed donor chimerism and age of patient, underlying diagnosis 
or donor type.  
2 patients received DLI for persistent mixed chimerism (1 in the context of presumed PTLD with rising B cell 
numbers and FDG-avid lymphadenopathy on PET/CT scan). One achieved full donor chimerism in B cells and 
granulocytes with T cells remaining mixed and the other converted to full donor chimerism.  
There were no cases of graft rejection and in all surviving patients either stable mixed chimerism or full 
donor chimerism were observed. 
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PID-associated Colitis  
Of the 10 patients with moderate-severe inflammatory bowel disease pre-transplant (6 CGD, 1 XIAP, 1 CVID, 
1 ALPS and 1 DCML deficiency), two died of TRM (both with CGD, patients 21 and 23) and the colitis has 
resolved in all 8 surviving patients, including the XIAP patient. No increased incidence of gut GVHD was 
observed in these patients. 
 
 
DISCUSSION 
 
We have demonstrated that in 29 young adult patients with high-risk primary immune deficiencies, reduced-
intensity, in vivo T cell depleted Allo-HSCT was both effective and safe, with an overall survival of 85.2% at 3 
years and a mean follow-up of 3.5 years (41 months). There was no significant difference in outcome 
between those undergoing matched related donor transplants and matched, or 1 antigen mismatched 
unrelated donor transplants (p=0.51). As predicted using our previously described T cell-depleting 
conditioning regimens, the observed cumulative incidence of severe acute GVHD incidence (grades III-IV) 
was very low at 6.5% and only 31% of patients developed chronic GVHD, symptoms which resolved allowing 
withdrawal of systemic immune suppression from 3 months post transplant in all but one of these patients. 
Full multilineage donor chimerism was achieved in 42% of patients, and all others achieved stable mixed 
chimerism. Larger studies are required to determine the degree of donor chimerism required post transplant 
for some of the rarer PIDs in order to achieve a functional cure. Good functional immune reconstitution was 
observed in all but one of the patients permitting the withdrawal of immunoglobulin replacement therapy 
post-transplant in 89% of patients. At last follow up 92% of surviving patients (n=24) were off immune 
suppression and the remaining two were in the process of weaning.  
 
The overall and event free survival observed in this series of adult patients is comparable or better than that 
seen in published series of Allo-HSCT outcomes for pediatric and adolescent patients with PID and CGD
9, 23, 34-
36
.  
 
The patients in this study had not undergone Allo-HSCT earlier in life due to a variety of reasons including 
mild-moderate clinical phenotype in childhood therefore not precipitating referral, delay in diagnosis until 
adolescence/adulthood, late presentation, and/or lack of a suitable donor. Patients had subsequently 
developed complications that necessitated definitive treatment in the form of Allo-HSCT. Triggers for referral 
included life-threatening infection, malignancy, autoimmune or inflammatory phenomena, newly confirmed 
genetic diagnosis or new donor availability. Due to pre-existing organ dysfunction, ongoing infectious or 
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inflammatory phenomena all patients in this cohort had a HCT-CI of at least 1 whilst 12 had a score of 3 or 
greater predicting a higher than observed TRM
25, 37
. Both the HCT-CI score or European Group for Blood and 
Bone Marrow Transplantation (EBMT) score have been validated in patients with haematological 
malignancies and in paediatric populations
38, 39
. Neither score has been validated in patients with PID or 
specifically CGD however it provides validated information on the clinical condition of patients pre-
transplant. Patients with cellular immunodeficiency have been shown to have a higher HCT-CI and this score 
is used most frequently in other published studies of HSCT in PID
25
. 
 
These promising results suggest that Allo-HSCT is safe when delivered in a specialist centre and should be 
considered as a potentially curative option for younger adult PID patients with an appropriate donor and a 
sufficiently severe clinical picture. We recommend proceeding to Allo-HSCT for adult patients with a known 
genetic diagnosis amenable to correction by transplantation, and where conservative management results in 
a shortened life expectancy and ongoing morbidity. The current widespread use of next generation 
sequencing is expected to facilitate earlier referral of eligible adults. 
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FIGURE TITLES AND LEGENDS 
 
Figure 1.  Probabilities of overall survival (OS) and event-free survival (EFS) 
(A) OS for the whole cohort was 89.2% at 12 months and 85.2% at 3 years (B) OS for matched related donors 
(MRD) 90.9% and 77.9% at 1 and 3 years respectively. OS for matched unrelated donors/mis-matched 
unrelated donors (MUD/MMUD) transplants was 94.4% and 88.9% at 1 and 3 years respectively, p=0.51. (C) 
OS for PID patients 94.4% and 88.9% at 1 and 3 years respectively. OS for adults for CGD patients was 90.9% 
and 81.8% at 1 and 3 years, p=0.75 (D) EFS 89.7% at 1 and 3 years. (E) EFS for MRD transplants 90.9% at both 
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1 and 3 years.  EFS MUD/MMUD transplants 88.9% at 1 and 3 years, p=0.73  (F) EFS for PID patients 88.9%, 
EFS for CGD patients 90.9% at both 1 and 3 years, p=0.65. 
 
Figure 2.  Hematopoietic engraftment kinetics. 
(A) Cumulative incidence of neutrophil engraftment (defined as >0.5x10
9
/L for 3 consecutive days). Median 
time to neutrophil engraftment was 11 days in matched related donor (MRD) transplants and 15 days in 
MUD/MMUD transplants. (B) Cumulative incidence of neutrophil engraftment in the two main diagnostic 
groups. Median time to neutrophil engraftment was 11 days in non-CGD PIDs and 16 days in CGD patients. 
(C) Cumulative incidence of platelet engraftment (defined as >50x10
9
/L for 3 consecutive days). Median time 
to platelet engraftment was 12 days in MRD transplants and 18 days in MUD/MMUD transplants. (D) 
Cumulative incidence of platelet engraftment in the two main diagnostic groups. Median time to platelet 
engraftment was 16 days in non-CGD PIDs and 19 days in CGD patients. 
 
Figure 3.  Cumulative incidence of transplant related mortality (TRM). 
(A) Transplant related mortality (TRM) for all patients was 11% (n=29) at 1 year and 15% at 3 years. (B) TRM 
for patients with matched related donors (MRD) was 10% at 1 year and 22% at 3 years (n=11) vs 11% at 1 
year and 3 years for MUD/MMUD transplants (n= 18), p=0.536 (C) TRM for patients with CGD was 10% at 1 
year and at 3 years (n=11) vs other PID 12% at 1 year and 3 years (n=18), p=0.73. 
 
Figure 4: Peripheral blood chimerism post transplant. 
(A) PBMC chimerism results at 3, 6 and 12 months (n = 20, 17 and 19 respectively): Full donor chimerism 
(≥97% donor DNA) was achieved in PBMC fraction in 71% at 3 months, 83% at 6 months and 85% at 12 
months. (B) T cell chimerism results: full donor chimerism was achieved in the T cell fraction in 30% at 3 
months, 41% at 6 months and 52% at 12 months. (C) B cell chimerism: Full donor chimerism was achieved in 
the B cell fraction in 65% at 3 months, 82% at 6 months and 69% at 12 months. (D) Chimerism in the 
granulocyte fraction. Full donor chimerism was seen in 83% patients at 3 months, 67% at 6 months and 67% 
at 12 months. 
 
  
Diagnosis Genetic Mutation Age at 
Diagnosis 
Age at 
HSCT/Sex 
Medical Complications Prior to Transplant HCT-CI 
Score* 
Donor (HLA 
mis-match) 
Stem cell 
source 
CD34 dose 
x 10
6
/kg 
CMV Status 
(R/D) 
Conditioning 
Regimen 
In vivo  
T-cell depletion 
(dose) 
GVHD 
Prophylaxis 
CVID Not done. 20 31/F Red cell aplasia. 2 MRD PBSC 10.8 +/+ Flu Mel Alemtuzumab  
(100mg) 
CSA 
Granulomatous CVID  No mutation in TNFSF5. 
(Normal T cell numbers at 
presentation and no T cell 
related infections). 
15 30/F Inflammatory lung disease, sclerosing cholangitis, prior 
splenectomy, pulmonary fibrosis, pulmonary aspergilloma*, 
osteopenia. 
≥3 MUD PBSC 15.3 +/+ Flu Mel Alemtuzumab 
(100mg) 
CSA 
APDS2 Splice donor mutation in 
PIK3R1 (predicting exon 
skipping). 
10 50/M Severe lymphatic pan-colitis, previous mycoplasma arthritis, 
bronchiectasis, previous peripheral CD8+ T cell NHL, pulmonary 
hypertension. 
≥3 MUD PBSC 5.1 +/+ Flu Mel Alemtuzumab 
(100mg) 
CSA 
Autoimmune LPD Heterozygous TNFRSF 6 gene 
encoding Fas (c.785T>C 
(I232T). 
3 32/M Refractory thrombocytopenia, previous splenectomy, hypertension. 2 MRD PBSC 3.7 +/- Flu Mel 
 
Alemtuzumab 
(100mg) 
CSA 
Autoimmune LPD No mutation identified, 
including in Fas, SH2D1A. 
Functional apoptosis defect. 
32 34/M Indolent lymphoma (NHL), autoimmune neutropenia, MGUS with 
IgG paraprotein, previous splenectomy, Factor XI deficiency. 
1 MUD PBSC 6.7 -/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
Cγ-chain SCID Confirmed by sequencing. 1 26M Failed haploidentical allo and gene therapy. Sclerosing cholangitis. 
Recurrent infections. Bronchiectasis and pneumocele. Brachio-
cephalic thrombus. Hepatomegaly with chronic cholangiopathy. 
Refractory facial planar warts. Depression. 
≥3 MUD PBSC 12.6 +/+ Flu Mel Alemuzumab 
(100mg) 
CSA 
Absolute NK deficiency, 
Hypogammaglobulinaemia 
No mutation identified. Whole 
genome sequencing pending. 
14 27/M Refractory planar warts (HPV2)
$
, recurrent infections, 
bronchiectasis, sarcoid arthropathy, IgG 1 and 2 subclass deficiency.   
≥3 MRD PBSC 7.8 +/+ Flu Mel Alemtuzumab  
(30mg) 
CSA 
DCML deficiency Gata2 wild type; Whole 
exome sequencing 
Pending. 
24 27/F Trilineage MDS, bronchiectasis, Crohn’s colitis, recurrent viral warts, 
Mycobacterium avium complex, anal and vulval intraepithelial 
neoplasia (HPV)
$
. 
≥3 MMUD  
(C Ag) 
PBSC 6.3 +/+ Flu Mel Alemtuzumab 
(100mg) 
CSA 
AR  IL12Recβ deficiency Confirmed by sequencing. 19 29/M Recurrent salmonella sepsis, salmonella pericarditis with cardiac 
tamponade, mild asthma, recurrent otitis externa. 
≥3 MMUD  
(A Ag) 
PBSC 7.0 -/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
 Rag2/red cell aplasia RAG2 (c.104G>T 
(Gly35Val)/het and c.814G>A 
(Val72Ile)/het 
andc.965T>C(Met 322Thr)Het. 
16 20/M Red cell aplasia, granulomatous skin lesions, high transfusion 
requirement and iron overload, chronic clonal NK cell proliferation, 
EBV viraemia. 
≥3 MUD PBSC 5.4 -/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
 X-linked LPD Confirmed by sequencing. 3 18/M B cell NHL, hypogammglobulinaemia. 1 MRD PBSC 11.0 +/+ Flu Mel Alemtuzumab 
(100mg) 
CSA 
 Undefined CID c.205del heterozygote in CD27 
gene.  
Heterozygous mutations in 
CD27, LRBA, LYST and PRKDC. 
11 22/M EBV viraemia, atypical stage 4B T cell rich B cell NHL, LP HL (R-CHOP 
x6, high dose MTX). 
2 MUD PBSC 4.0 +/+ Flu Mel Alemtuzumab 
(100mg) 
CSA 
 CD27 deficiency CD27 (c.251_252insT 
(C71Lfs*4) and SNP in exon 3 
371761387). 
13 18/M Nodular sclerosing HL, EBV+ Stage IV Diffuse Large B cell 
Lymphoma. 
1 MMUD  
(A Ag) 
PBSC 6.4 -/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
 Gata2 deficiency 735-736insC Amino Acid Subs 
P245fs 
20 22/F MDS, persistent viral warts, mild IgG hypogammaglobulinaemia, 
CD19, CD56 Lymphopenia, HPV VIN3
$
. 
1 MUD PBSC 6.3 +/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
 XIAP deficiency XIAP - absent by FACs (2 
centres); 
No mutation identified. 
19 21/M HLH, Crohn’s (requiring pan-colectomy as a child). ≥3 MRD PBSC 4.7 -/+ Flu Mel Alemtuzumab 
(30mg) 
CSA 
 Autoimmune LPD I246T Fas Mutation 2 21/F Relapsed Hodgkin’s lymphoma, autoimmune haemolysis, genital 
HSV, previous splenectomy, juvenile inflammatory arthropathy, 
patchy colonic lymphocytic infiltration. 
2 MRD PBSC 2.1 +/+ Flu Mel Alemtuzumab 
(30mg)  
CSA 
 Gata 2 mutation Frame duplication of 6 
nucleotides not previously 
reported. 
19 22/F MDS with profound monocytopenia, prolonged severe EBV 
infection with hepatitis and meningoencephalitis. 
≥3 MRD PBSC 2.0 -/- Flu Mel Alemtuzumab  
(30mg) 
CSA 
 XIAP 
deficiency 
Sequence variant c.497G>A in 
exon 2 of the XIAP gene. Not 
previously reported.  
4 24/M EBV lymphoproliferative disease x2 episodes, 
hypogammaglobulinaemia, splenomegaly, granulomatous 
lymphocytic inflammatory lung disease with bronchiectasis.  
2 MRD PBSC 5.5 +/- Flu Mel Alemtuzumab 
(30mg) 
CSA 
 AR-CGD P47 deficiency identified on 
FACs analysis. 
12 18/M Recurrent infections including staphylococcal abscesses. 1 Father 
10/10 
BM 3.7 +/+ Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
 AR-CGD p47 deficiency identified on 
FACs analysis. 
18 19/M Recurrent infections , chronic relapsing multifocal osteomyelitis, 
mould pulmonary infection, dyslexia. 
2 MUD BM 2.1 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  AR-CGD NCF-1 (P47 deficiency by 
FACS. Homozygous for 
c.579g>A (Trp193X). 
3 27/F Recurrent infections including presumed nocardia meningitis. 
Severe inflammatory bowel disease necessitating subtotal 
colectomy and ileostomy formation. Colonised with resistant 
pseudomonas. 
≥3 MUD BM 6.3 +/+ Flu Bu Alemtuzumab 
(0.6mg/kg) 
CSA 
 Table 1: Patient demographics and transplant characteristics. 
CVID common variable immunodeficiency; LPD lymphoproliferative disease; SCID severe combined immunodeficiency; NK natural killer cell; DCML dendritic 
cell, monocyte, B lymphocyte, and natural killer lymphocyte deficiency; AR autosomal recessive; CID combined immunodeficiency; XIAP X-linked inhibitor of 
apoptosis protein deficiency; CGD chronic granulomatous disease; APDS2 Activated PI3Kδ syndrome type 2; MUD matched unrelated donor; MMUD 
mismatched unrelated donor; MRD matched related donor; PBSC peripheral blood stem cells; BM bone marrow; CSA cyclosporin A; Flu fludarabine; Bu 
busulphan; Mel melphalan, rATG rabbit anti-thymocyte globulin; FACs fluorescence-activated cell sorting; HCT-CI hematopoietic cell transplant comorbidity 
index; R/D recipient/donor CMV sero status; *active infection at transplant; 
$
unresolved viral warts at transplant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Variant CGD NCF-1 (Fusion of NCF-1 and 
pseudo NCF-1 with crossover 
between exon 4 and exon 16). 
24 28/F Severe Crohn’s disease with perineal and perianal disease requiring 
colectomy and proctectomy with ileostomy. 
1 MUD PBSC 14.5 -/- Flu Bu  rATG 
(7.5mg/kg) 
CSA 
  X-linked CGD CYBB (c.G764A(Trp251*)) 
 
1 27/M Recurrent infections, severe colitis. 2 MRD PBSC 5.0 +/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
 X-linked CGD p47 deficiency identified on 
FACs analysis. 
2 18/M Pan-colitis, previous hemicolectomy for stricture of ascending colon, 
recurrent infections, renal impairment. 
≥3 MUD BM 4.2 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  X-linked CGD CYBB (TC342/343>AT 
(His115Tyr)). 
 
4 19/M Recurrent fungal chest infections, extensive granulomas, growth 
failure, previous gene therapy (August 2007) with transient 
engraftment. 
≥3 MMUD  
(A Ag) 
PBSC 32.3 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  X-linked CGD GP91 intron6 gtg>atg 1 19/M Recurrent infections including osteomyelitis and fungal chest 
infection (aspergillus nidulans). 
1 MMUD  
(A Ag) 
BM 0.3 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  X-linked CGD GP91phox 20kb deletion 
leading to complete absence 
of CYBB and Kell genes 
(McLeod Phenotype).  
At birth 17/M Pan-colitis, recurrent infections, McLeod phenotype. 2 MUD BM 1.4 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  X-linked CGD NCF1 (c.579G>A (TRP193*). 16 23/M Recurrent infections including staphylococcal skin abscesses, 
progressive granulomas. 
2 MRD PBSC 4.1 +/- Flu Mel Alemtuzumab 
(100mg) 
CSA 
  X-linked CGD Gp91absent by FACs. 2 months 17/M Progressive colitis, multiple infective complications. 
 
2 MUD BM 1.9 -/- Flu Bu  Alemtuzumab 
(0.6mg/kg) 
CSA 
  
 
 
 
 
 
 
  
 
Diagnosis Acute 
GVHD 
(grade) 
Chronic 
GVHD 
CMV 
Status 
(R/D) 
Infectious Complications Other complications Days 
 FU 
 
 
Present  
Status 
Immuno- 
Suppression 
at last FU 
 (Y/N) 
Immunoglobulin  
replacement  
(Continues, Off or N/A) 
Peripheral Blood Chimerism  
at last F/U 
(PBMC)* 
Outcome 
1 
 
CVID N/A N/A +/+ Sepsis. Multi organ failure. 12 Dead. Y N/A N/A. Died TRM (sepsis). 
2 
 
CVID None. Probable 
Pulmonary. 
+/+ CMV reactivation. Recurrent 
bacterial chest infection.  
ITP. Progressive pulmonary 
fibrosis/bronchiolitis obliterans. 
3434 Dead. Y Continued until death. Full donor chimerism Died (progressive respiratory failure 
secondary to pre-existing pulmonary 
fibrosis +/- pulmonary GVHD).  
3  
 
APDS2 Grade 1 
gut 
Limited 
(gut). 
+/+ Intermittent respiratory 
tract infections. 
Papillary renal cell carcinoma (unrelated) 730 Alive. N Off Full donor chimerism Well.  
4 
 
Autoimmune 
LPD 
None. Limited post 
DLI. 
+/- None. Oesophageal stricture secondary to 
peptic ulceration. DLI x 3 for mixed 
chimerism. 
4358 Alive. N N/A Full donor chimerism Well.  
5 
 
Autoimmune 
LPD 
None. None. -/- None. CSA-induced neurotoxicity  
DLI x 4 for presumed PTLD (no biopsy, 
FDG-avid lymphadenopathy on CT/PET 
scan). 
3378 Alive. N Off Full donor chimerism Well. Neurotoxicity resolved.  
6 
 
Cγ-chain SCID N/A N/A +/+ Sepsis. Multi organ failure. 7 Dead. Y N/A N/A Died TRM (sepsis). 
7 
 
Absolute NK 
deficiency 
Grade 1 
skin. 
None. +/+ Persistent planar warts 
(HPV2). 
None. 2015 Alive. N Off Full donor chimerism Persistent extensive warts.  
8  
 
DCML 
deficiency 
Grade 2 
skin & 
gut. 
None. +/+ CMV reactivation (resolved). 
Radial excision for persistent 
HPV associated AIN and VIN. 
Acute thyroiditis (antibody negative). 
Ovarian failure.  
1221 Alive. N N/A Full donor chimerism Well. Thyroiditis resolved. GVHD 
resolved. 
9 
 
AR  IL12Recβ 
deficiency 
Grade 1 
skin. 
Limited 
(gut). 
-/- EBV reactivation treated 
with rituximab. 
None. 1083 Alive. N Off Full donor chimerism Well.  
10 
 
Rag2/red cell 
aplasia 
None. None.  -/- None. Delayed engraftment. 700 Alive. N Off Stable mixed chimerism (full 
donor in B cell fraction, mixed 
in other lineages). 
Well. Resolution of granulomatous skin 
lesions on shins.  
11 
 
X-linked LPD None. None. +/+ BK virus cystitis. None. 3692 Alive. N Off Stable mixed chimerism 
(mixed all lineages). 
Well. Normal spermatozoa.  
12 
 
Combined 
immune 
deficiency 
Grade 2 
skin. 
None. +/+ CMV reactivation. Intermittent neutropenia. 1042 Alive. N Continues Stable mixed chimerism 
(mixed all lineages).  
Well.  
13 
 
CD27 
deficiency 
Grade 2 
skin. 
Limited 
(skin). 
-/- Rhinovirus. EBV reactivation 
treated with rituximab. 
None. 544 Alive. N Continues Full donor chimerism Well. CT/PET ongoing remission.  
14 
 
Gata2 
deficiency 
None. None. +/- Persistent perineal HPV with 
VIN3. 
 
DLI x 3 for MC. Fibromyalgia. Chronic 
fatigue. Thyrotoxicosis 
1051 Alive. N N/A Full donor chimerism Well. Resolution of warts on hands & 
feet.  
15 
 
XIAP 
deficiency 
None. None. -/+ Warts left foot and right 
index finger resolving. 
None. 629 Alive. N N/A Stable mixed chimerism 
(mixed all lineages).  
Well. No further colitis.  
16 
 
Autoimmune 
LPD 
Grade 2 
skin. 
None. +/+ CMV reactivation x 1. Biopsy proven EBV PTLD treated with 4 
cycles rituximab.  
118 Alive. N N/A Chimerism pending Well. No further CMV or EBV 
reactivations.  
17 
 
Gata 2 
mutation 
Grade 1 
skin. 
None. -/- Low level EBV reactivation 
not requiring intervention. 
None. 209 Alive. Y N/A Full donor chimerism Well. Weaning cyclosporin. 
18 
 
XIAP 
deficiency 
None. None. +/-  None. Slow recovery of counts and persistent 
splenomegaly. 
115 Alive. Y Off Full donor chimerism Well. Weaning cyclosporin. Trial off 
Immunoglobulin as IgG in normal range 
at 4m post.  
19 
 
AR-CGD None. None. +/+ CMV reactivation. Iron and vitamin D deficiency. 983 Alive. N N/A Stable mixed chimerism 
(mixed all lineages). 
 
Well. Viable sperm.  
20 
 
AR-CGD None. None. -/- None. None. 971 Alive. N N/A Stable mixed chimerism (full 
donor in PBMCs and B cells, 
mixed in T cell and 
granulocyte fractions) 
Well.  
21  
 
AR-CGD None. None. +/+ Bilateral lower lobe 
consolidation (no organisms 
Haemophagocytosis and prolonged 
cytopenias; Granulomatous meningitis 
210 Dead. Y N/A Full donor chimerism Died TRM (multi-organ failure). 
identified) (no pathogen identified); Acute hepatic 
failure. 
22 
 
Variant CGD Grade 1 
skin. 
None. -/- None. Premature ovarian insufficiency. 992 Alive. N N/A Stable mixed chimerism (full 
donor in B cell fraction, mixed 
in other lineages). 
Well. Resolution of granulomatous 
colitis.  
23  
 
X-linked CGD Grade 3 
liver. 
Steroid 
refractory, 
extensive. 
+/- Multiple infective 
complications associated 
with immune suppression 
for GVHD. 
 616 Dead. Y N/A Full donor chimerism Died TRM (steroid refractory extensive 
cGVHD).  
24 
 
X-linked CGD None. None. -/- None. Mild renal impairment. 1858 Alive. N N/A Stable mixed chimerism 
(mixed in all lineages). 
Well. Renal impairment resolved.  
25  
 
X-linked CGD Grade 1 
skin. 
None. -/- Adenoviraemia.  EBV PTLD treated with 4 cycles 
rituximab. 
1003 Alive. N N/A Full donor chimerism Well.  
26  
 
X-linked CGD Grade 1 
skin. 
Limited 
(skin). 
-/- Pulmonary aspergillosis. Renal impairment (resolved), CD34+ top 
up for prolonged cytopenias. 
1319 Alive. N N/A Full donor chimerism Well. Some viable sperm suitable for 
ICSI.  
27  
 
X-linked CGD Grade 1 
skin. 
Limited 
(skin). 
-/- None. None. 857 Alive. N N/A Stable mixed chimerism (full 
donor in PBMC and B cell 
fractions, mixed in T cell and 
granulocyte fractions).  
Well. Viable sperm on testing, suitable 
for ICSI.  
28  
 
X-linked CGD None. None. +/- None. DLI x 4 for mixed chimerism. 3516 Alive. N N/A Stable mixed chimerism 
(mixed in all lineages) 
Well. Normal full blood count. Father of 
2 children.  
29  
 
X-linked CGD None. None. -/- Rotavirus diarrhoea. Depression. 697 Alive. N N/A Stable mixed chimerism (full 
donor in PBMC and B cell 
fractions, mixed in T cell and 
granulocyte fractions).  
Well.  
 
Table 2: Transplant outcome and resolution of PID-related complications. 
GVHD graft versus host disease; R/D recipient/donor CMV sero status; FU follow up; TRM transplant related mortality;  ITP idiopathic thrombocytopenic 
purpura;  DLI donor lymphocyte infusion;  PTLD post transplant lymphoproliferative disease;  HPV human papilloma virus;  AIN/VIN/CIN anal/vaginal/cervical 
intraepithelial neoplasia;  EBV  Epstein Barr  virus;  MC mixed chimerism;  ICSI  intracytoplasmic sperm injection; N/A Not applicable;  Full donor  ≥97% donor 
DNA; Mixed chimerism  ≥ 50% < 97% donor DNA; * See Figure 4 for lineage specific chimerism.
  
 
Figure'1.''Probabili/es'of'overall'survival'(OS)'and'event:free'survival'(EFS).'
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Figure'3.''Cumula.ve'incidence'of'transplant'related'mortality'(TRM).#'
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